ALS drug wins U.S. FDA approval despite questionable data – CTV

    You can use your smart phone to browse stories in the comfort of your hand. Simply browse this site on your smart phone.

    Using an RSS Reader you can access most recent stories and other feeds posted on this network.

    SNetwork Recent Stories

ALS drug wins U.S. FDA approval despite questionable data – CTV

by tmnationtalk on September 30, 2022103 Views

Sept. 30, 2022

A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.

The Food and Drug Administration approved the drug from Amylyx Pharmaceuticals based on results from one small, mid-stage study in which patients with the debilitating disease appeared to progress more slowly and survive several months longer. Typically, the FDA requires two large studies or one study with “very persuasive” survival results for approval.

“This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” FDA’s neurology drug director Dr. Billy Dunn said in a statement.

The drug, Relyvrio, is the third U.S.-approved medicine for amyotrophic lateral sclerosis, or ALS, which destroys nerve cells needed for basic functions like walking, talking and swallowing. About 20,000 people in the U.S. are living with the disease.

Read more: https://www.ctvnews.ca/health/als-drug-wins-u-s-fda-approval-despite-questionable-data-1.6090735

Send To Friend Email Print Story

Comments are closed.

NationTalk Partners & Sponsors Learn More

CLOSE
CLOSE